Teva has announced the US launch of the ProAir Digihaler albuterol DPI for the treatment of bronchospasm. The list price for the inhaler will be $146.67. ProAir Digihaler, which includes built-in sensors connected to a mobile app via Bluetooth, was approved by the FDA in December 2018.
The company said that it also has plans to launch the AirDuo Digihaler fluticasone propionate/salmeterol and ArmonAir Digihaler fluticasone propionate DPIs in the next few months. The FDA approved AirDuo Digihaler in July 2019 and ArmonAir Digihaler in February 2020.
Teva Pharmaceuticals Executive VP, North American Commercial, Brendan O’Grady commented, “The launch of ProAir Digihaler and its companion app provides a great opportunity for bringing a new digital health tool to asthma and COPD patients in the US. We are especially proud to provide our first Digihaler product at a time when digital health technology is growing and continues to transform patient care, since it will enable patients to electronically record and monitor their rescue inhaler use.”
Executive VP, Global Marketing & Portfolio, Sven Dethlefs added, “It is our belief that ProAir Digihaler and the companion app will help address an unmet need for HCPs by providing objective rescue inhaler use data when managing their patients. Ultimately, this technology may help patients who use ProAir Digihaler and its accompanying app to have a better-informed dialogue with their HCP about their disease management and treatment decisions.”
Read the Teva press release.
